Our key feature this month is a review of the UK/EU Electricity sector by Nigel Hawkins who has recently joined Hardman to cover the utilities and renewable energy market. Nigel
Demand for the Group’s core ventilation products is benefiting from dynamic building methods, tightening regulation and increasing focus on healthy buildings. What is more, almost half of Group revenue is
Verona Pharma Plc (LON:VRP) is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly
This month’s feature article is the first publication of the top 15 drug companies in the 2015 global industry ranking and how this has changed over the last decade. In
Alliance Pharma Plc (LON:APH) has developed through a series of 28 acquisitions as part of a buy and build strategy, culminating in the most recent £127.5m acquisition of 27 primarily
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being
Avacta Group Plc (LON:AVCT) is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and
Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, regenerative medicine, and in vitro diagnostic products. It aims to
Primary Health Properties Plc (LON:PHP) reported final results 4th February and 2015’s dividend cover rose to 107% in second half. FY 2016 we estimate 105% cover. There have been 19
By Charles Breese, Managing Director of Larpent Newton and Co Ltd. The timing of being invited to write this article is perfect, coinciding as it does with a) the huge
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
